BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1197 related articles for article (PubMed ID: 18093827)

  • 1. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
    Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
    Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
    Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
    J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
    Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer.
    Moehler M; Galle PR; Gockel I; Junginger T; Schmidberger H
    Best Pract Res Clin Gastroenterol; 2007; 21(6):965-81. PubMed ID: 18070698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized adenocarcinoma of the esophagogastric junction--is there a standard of care?
    Power DG; Reynolds JV
    Cancer Treat Rev; 2010 Aug; 36(5):400-9. PubMed ID: 20117883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
    Veuillez V; Rougier P; Seitz JF
    Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of neoadjuvant therapy for esophageal adenocarcinoma.
    Ku GY; Ilson DH
    Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
    Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
    Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
    Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy of resected gastric cancer is necessary.
    Carrato A; Gallego-Plazas J; Guillen-Ponce C
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S105-8. PubMed ID: 16399445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric cancer.
    Catalano V; Labianca R; Beretta GD; Gatta G; de Braud F; Van Cutsem E
    Crit Rev Oncol Hematol; 2009 Aug; 71(2):127-64. PubMed ID: 19230702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601.
    Findlay M; Storey D; Gebski V; Hargreaves C; Cullingford G; Boyer M; Trotter J; Archer S; Davidson A; Johnston P; Yuen J; Dhillon H; Della-Fiorentina S; Richardson G; Truskett P; Goldstein D;
    ANZ J Surg; 2007 Apr; 77(4):247-52. PubMed ID: 17388828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical overview: adjuvant therapy of gastrointestinal cancer.
    Macdonald JS
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S4-11. PubMed ID: 15309508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of gastric cancer].
    Lordick F; Ridwelski K; Al-Batran SE; Trarbach T; Schlag PM; Piso P
    Onkologie; 2008; 31 Suppl 5():32-9. PubMed ID: 19033703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.